

# Press Release



## Walter Wenninger appointed to PAION's Supervisory Board

**Aachen (Germany), 21 August 2003** – PAION GmbH today announced that its shareholders have appointed Dr. Walter Wenninger as Vice-Chairman to the company's Supervisory Board.

Until 2000 Dr. Wenninger was a member of BAYER's Board of Management for six years. Prior to this he held various leading management positions at BAYER AG, Germany and in several of its subsidiaries in the US and Europe. His vast experience in the worldwide healthcare business has brought him various positions in institutions, such as the Robert Koch Foundation in Bonn, Germany as well as in the boards of young life science companies.

Dr. Wenninger substitutes Dr. André Lamotte. Dr. Lamotte is a co-founder and played an active role in PAION's fundraising and business development activities since the foundation of the company. He will continue to support PAION in these matters.

*"I am excited to support PAION in its further development. I think that PAION's lead product Desmoteplase is a highly promising drug and may open new ways to treat stroke patients. There is a great interest of several parties in partnering with PAION and I am positive that I can support the management team to identify the best possible way to capitalise on the expected positive Phase II results in the near future,"* says Walter Wenninger.

Wolfgang Soehngen, PAION's CEO comments: *„The appointment of Dr. Wenninger to PAION's Supervisory Board is the next step on PAION's way to position itself as a player in stroke. His extensive understanding of the various healthcare markets will be valuable as PAION moves closer to potential major partnering agreements and the market launch of its lead product Desmoteplase, a potent thrombolytic for the treatment of acute ischaemic stroke”.*

## **PAION GmbH**

PAION is a biopharmaceutical company based in Aachen, Germany, dedicated to the development of innovative therapeutic products for the treatment of stroke, thrombotic diseases and acute neuronal damage. The company has core competencies in international drug development and registration.

Having completed recruitment for its thrombolytic Desmoteplase in the clinical phase II trial DIAS (Desmoteplase In Acute ischaemic Stroke), PAION will present results to the public shortly.

The company is driven by an international management team and supported by a leading group of investors and opinion leaders. Thus, PAION is ideally equipped to launch a unique portfolio of stroke products onto the market and fulfil its vision of being the “PAIONeer in stroke”.

## **Contact**

### **PAION GmbH**

Birgit Jansen  
Head of Business Development & Communications  
Martinstr. 10-12, 52062 Aachen  
T: +49 (0)241 4453 150  
e: b.jansen@paion.de